DrugJul 15, 2026
QuVa Pharma Methohexital Sodium, 100 mg/10 mL (10 mg/mL), Total Volume: 10 mL recall — FDA D-0664-2026
Failed Impurities/Degradation Specifications
Class IIFDA: OngoingQuVa Pharma, Inc.
Recall history in this database
Classification mix: Class II: 5.
DrugNov 5, 2025
QuVa Pharma R.E.C.K recall — FDA D-0113-2026
Presence of Particulate Matter
Class IIFDA: OngoingQuVa Pharma, Inc.
DrugApr 2, 2025
QuVa Pharma fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.125% Bupivacaine HCl 125 mg/100 recall — FDA D-0296-2025
Lack of Assurance of Sterility
Class IIFDA: OngoingQuVa Pharma, Inc.
DrugApr 2, 2025
QuVa Pharma fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.1% Bupivacaine HCl 100 mg/100 recall — FDA D-0295-2025
Lack of Assurance of Sterility
Class IIFDA: OngoingQuVa Pharma, Inc.
DrugApr 2, 2025
QuVa Pharma fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.2% ROPivacaine HCl 200 mg/100 recall — FDA D-0297-2025
Lack of Assurance of Sterility
Class IIFDA: OngoingQuVa Pharma, Inc.
Understanding this recall history
This page summarizes recall records in which the official source identifies QuVa Pharma, Inc. as the recalling firm or manufacturer. The number of records should not be treated as a safety rating or a measure of company size, because recall counts depend on product mix, reporting periods and how government records are organized.
Compare the dates, categories and classifications together rather than relying on the total alone. Open an individual record for the recalled product, reason, distribution details and current instructions available from the source.